keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis C antiviral

keyword
https://www.readbyqxmd.com/read/29346260/race-risk-and-willingness-of-end-stage-renal-disease-patients-without-hepatitis-c-hcv-to-accept-an-hcv-infected-kidney-transplant
#1
Maureen McCauley, Adam Mussell, David Goldberg, Deirdre Sawinski, Rodolfo N Molina, Ricarda Tomlin, Sahil D Doshi, Peter Abt, Roy Bloom, Emily Blumberg, Sanjay Kulkarni, Gabriela Esnaola, Justine Shults, Carrie Thiessen, Peter P Reese
BACKGROUND: Despite effective antiviral treatment, hundreds of kidneys from deceased donors with hepatitis C virus (HCV) are discarded annually. Little is known about the determinants of willingness to accept HCV-infected kidneys among HCV-negative patients. METHODS: At 2 centers, 189 patients undergoing initial or reevaluation for transplant made 12 hypothetical decisions about accepting HCV-infected kidneys in which we systematically varied expected HCV cure rate, allograft quality and wait-time for an uninfected kidney...
January 18, 2018: Transplantation
https://www.readbyqxmd.com/read/29345844/assessing-hepatitis-c-spontaneous-clearance-and-understanding-associated-factors-a-systematic-review-and-meta-analysis
#2
Dewi Nur Aisyah, Laura Shallcross, Alice Jane Hully, Alastair O'Brien, Andrew Hayward
New advances in the treatment of hepatitis C provide high levels of sustained viral response but their expense limits availability in publicly funded health systems. The aim of this review is to estimate the proportion of patients who will spontaneously clear HCV and to identify factors that are associated with clearance, to support better targeting of directly acting antivirals. We searched Ovid Embase, Ovid Medline and Pubmed from 1st January 1994 to 30th June 2015 for studies reporting hepatitis C spontaneous clearance and/or demographic, clinical, and behavioural factors associated with clearance...
January 18, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29345798/clinical-impact-of-pharmacokinetic-interactions-between-the-hcv-protease-inhibitor-simeprevir-and-frequently-used-concomitant-medications
#3
Fiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, David Back, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, Markus Cornberg
AIMS: Direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug-drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (PK) interactions between simeprevir and frequently prescribed concomitant medications. METHODS: This post-hoc analysis pooled data from 9 studies which evaluated simeprevir (SMV)-based interferon-free HCV treatment...
January 18, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29345407/hepatitis-c-eradication-with-daa-and-risk-of-liver-cancer-recurrence-the-debate-unrests
#4
Massimo Colombo, Vincenzo Boccaccio
The advent of user friendly and highly successful oral regimens based on direct antiviral agents (DAA), has made a cure of hepatitis C possible in more than 95% of treated patients, including those who were considered difficult to cure with interferon, a vast category including patients with advanced liver disease and those who had a hepatocellular carcinoma (HCC) successfully eradicated by resection or local ablation1 . Despite low rates of treatment uptake and response to therapy with interferon, such hard to treat patients were able to gain significant health benefits, like halting of progression towards liver failure and prevention of second primary tumours, once replication of the hepatitis C virus (HCV) was permanently shut down2,3 ...
January 18, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29343250/evaluation-of-health-status-in-patients-with-hepatitis-c-treated-with-and-without-interferon
#5
R Ragusa, G Bertino, A Bruno, E Frazzetto, F Cicciu, G Giorgianni, L Lupo
BACKGROUND: The evolution of technology in healthcare has increased the health care's costs and, the universal healthcare systems, in developed countries, need to ensure proper allocation of resources. Thus, the major issue is assessing the effectiveness of new medical technologies. The evaluation of quality of life in response to new treatments has become a key indicator in chronic conditions for which medical interventions are evaluated not only in terms of increasing the number of expected life years but also in terms of increasing quality of life...
January 17, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29342358/synthesis-and-biological-characterization-of-aryl-uracil-inhibitors-of-hepatitis-c-virus-ns5b-polymerase-discovery-of-abt-072-a-trans-stilbene-analog-with-good-oral-bioavailability
#6
John Randolph, A Chris Krueger, Pamela Donner, John K Pratt, Dachun Liu, Christopher E Motter, Todd W Rockway, Mike D Tufano, Rolf Wagner, Hock B Lim, Jill M Beyer, Rubina Mondal, Neeta S Panchal, Lynn Colletti, Yaya Liu, Gennadiy Koev, Warren M Kati, Lisa E Hernandez, David W A Beno, Kenton L Longenecker, Kent D Stewart, Emily O Dumas, Akhteruzzaman Molla, Clarence Maring
ABT-072 is a non-nucleoside HCV NS5B polymerase inhibitor that was discovered as part of a program to identify new direct-acting antivirals (DAAs) for the treatment of HCV infection. This compound was identified during a medicinal chemistry effort to improve on an original lead, inhibitor 1, which we described in a previous publication. Replacement of the amide linkage in 1 with a trans-olefin resulted in improved compound permeability and solubility, and provided much better pharmacokinetic properties in preclinical species...
January 17, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29341280/editorial-direct-acting-antivirals-significantly-improve-quality-of-life-in-patients-with-hepatitis-c-virus-infection
#7
EDITORIAL
S Sanagapalli, M Danta
No abstract text is available yet for this article.
February 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29341278/editorial-direct-acting-antivirals-significantly-improve-quality-of-life-in-patients-with-hepatitis-c-virus-infection-author-s-reply
#8
EDITORIAL
Z M Younossi
No abstract text is available yet for this article.
February 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29341226/molecular-details-of-spontaneous-insertion-and-interaction-of-hcv-non-structure-3-protease-protein-domain-with-pip2-containing-membrane
#9
Huynh Minh Hung, Tran Dieu Hang, Minh Tho Nguyen
Hepatitis C virus (HCV), known as the leading cause of liver cirrhosis, viral hepatitis and hepatocellular carcinoma, has been affecting more than 150 million people globally. The HCV non-structure 3 (NS3) protease protein domain plays a key role in HCV replication and pathogenesis; and is currently a primary target for HCV antiviral therapy. Through unbiased molecular dynamics simulations which take advantage of the novel highly mobile membrane mimetic model, we constructed the membrane-bound state of the protein domain at the atomic level...
January 17, 2018: Proteins
https://www.readbyqxmd.com/read/29339926/using-a-chronic-hepatitis-b-registry-to-support-population-level-liver-cancer-prevention-in-sydney-australia
#10
Monica C Robotin, Ximena Masgoret, Mamta Porwal, David Goldsbury, Chee Khoo, Jacob George
Background: Approximately 1% of Australians have chronic hepatitis B (CHB), which disproportionately affects people born in hepatitis B-endemic countries. Currently, approximately half of the people affected remain undiagnosed and antiviral treatment uptake is suboptimal (~5%). This increases the likelihood of developing end-stage disease complications, particularly hepatocellular cancer (HCC), and largely accounts for the significant increases in HCC incidence and mortality in Australia over the last decades...
2018: Clinical Epidemiology
https://www.readbyqxmd.com/read/29337848/identifying-pre-existing-ns3-and-ns5a-resistance-associated-variants-and-transmission-chains-in-the-polish-hiv-hcv-genotype-1-epidemic-impact-on-prevention-and-treatment
#11
Miłosz Parczewski, Iwona Cielniak, Justyna Kordek, Bogusz Aksak-Wąs, Anna Urbańska, Magdalena Leszczyszyn-Pynka, Ewa Siwak, Monika Bociąga-Jasik, Anna Nowak, Aleksandra Szymczak, Małgorzata Zalewska, Władysław Łojewski, Anne-Mieke Vandamme, Nadine Lübke, Lize Cuypers
BACKGROUND: Hepatitis C virus (HCV) resistance-associated variants (RAVs) have been shown to adversely affect treatment response of direct-acting antivirals (DAAs). Identifying pre-existing RAVs and transmission networks among HIV/HCV genotype 1 (G1) infected patients from Poland will assist in shaping surveillance strategies for HCV. METHODS: NS3 and NS5A sequences were obtained from samples of 112 DAA-naive G1 patients (45 G1a, 67 G1b), of which 74 were chronically infected and 38 were diagnosed with acute hepatitis C (AHC)...
January 15, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#12
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29335738/remission-of-psoriasis-after-treatment-of-chronic-hepatitis-c-virus-infection-with-direct-acting-antivirals
#13
Masaru Enomoto, Chiharu Tateishi, Daisuke Tsuruta, Akihiro Tamori, Norifumi Kawada
No abstract text is available yet for this article.
January 16, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29334502/risk-of-hepatitis-b-virus-reactivation-among-patients-treated-with-ledipasvir-sofosbuvir-for-hepatitis-c-virus-infection
#14
Beshoy T Yanny, Nyan L Latt, Sammy Saab, Steven Han, Gina Choi, Jason Kramer, Amandeep K Sahota
BACKGROUND: Direct acting antiviral (DAA) agents are the standard of care for treatment of hepatitis C virus (HCV)-infected individuals. Hepatitis B virus (HBV) reactivation during HCV treatment has been reported, the incidence and clinical outcome remains unclear. The aim of our study is to examine the risk of HBV reactivation in actively infected or previously exposed patients during or after HCV treatment with DAAs. METHODS: Adults with chronic HCV infection previously exposed or actively infected with HBV and treated with DAAs between December 2015 to 2016 were included...
January 12, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29333065/hepatitis-c-infection-in-patients-with-hereditary-bleeding-disorders-epidemiology-natural-history-and-management
#15
REVIEW
Nikolaos Papadopoulos, Vasiliki Argiana, Melanie Deutsch
Hereditary bleeding disorders include a group of diseases with abnormalities of coagulation. Prior to 1990, infection with hepatitis C virus (HCV) was mainly transmitted via pooled plasma products as a treatment for hereditary bleeding disorders. Anti-HCV positivity in these patients may be as high as >70% in some areas, while some of them have also been coinfected with human immunodeficiency virus. Since about 20% of HCV-infected patients clear the infection naturally, chronic HCV infection represents a significant health problem in this group of patients...
January 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29329373/co-existing-hepatitis-c-and-alcoholic-liver-disease-a-diminishing-indication-for-liver-transplantation
#16
Amanda Wieland, Gregory T Everson
Aims: To provide an overview of published literature on the interaction of alcohol and hepatitis C virus (HCV) in the accelerated progression of liver disease to cirrhosis as relates to decision-making for the management of the liver transplant candidate and recipient. Methods: General PubMed search was employed along with expert input to identify the relevant articles on the topic. The authors also utilized both backward and forward citation review of the relevant articles and reviews to identify articles on identified topic...
January 10, 2018: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/29327780/systematic-review-with-meta-analysis-effectiveness-and-tolerability-of-interferon-free-direct-acting-antiviral-regimens-for-chronic-hepatitis-c-genotype-1-in-routine-clinical-practice-in-asia
#17
REVIEW
F Ji, B Wei, Y H Yeo, E Ogawa, B Zou, C D Stave, Z Li, S Dang, N Furusyo, R C Cheung, M H Nguyen
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017...
January 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29326009/is-there-sufficient-evidence-to-repeal-three-decades-of-clinical-research-on-chronic-hepatitis-c
#18
Giuseppe Ippolito, Alimuddin Zumla, Simone Lanini
The Cochrane Collaboration has published a systematic review about the treatment chronic hepatitis C (CHC) with direct-acting antivirals (DAAs) concluding that there is no evidence either to confirm or to reject the premise that DAAs have any clinical effects and they also state that sustained virological response is an unreliable surrogate marker to assess clinical efficacy. Here we discuss the implication of the Cochrane Collaboration review at the light of the current knowledge of CHC clinical management and propose a framework for the future research...
January 8, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29325996/direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection-in-the-kidney-transplant-recipient
#19
REVIEW
Donald F Chute, Raymond T Chung, Meghan E Sise
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated with increased morbidity and mortality compared with recipients who do not have chronic HCV infection. Because interferon-α-based therapies can precipitate acute rejection, they are relatively contraindicated after kidney transplantation. Thus, the majority of kidney transplant recipients with HCV remain untreated. There are now all-oral, interferon-free direct-acting antiviral therapies for HCV infection that are extremely effective and well tolerated in the general population...
January 9, 2018: Kidney International
https://www.readbyqxmd.com/read/29325299/-hepatitis-c-related-hepatocellular-carcinoma-and-the-treatment-with-direct-acting-antiviral-agents
#20
X Liu, Y H Gao, J Q Niu
With the wide use of direct-acting antiviral agents (DAAs), more and more patients with chronic hepatitis C achieve sustained virological response; however, no consensus has been reached on the application of DAAs in the treatment of hepatitis C virus-related hepatocellular carcinoma (HCC). This article summarizes and evaluates related issues in this field, including whether antiviral therapy with DAAs in patients with hepatitis C can increase the incidence or recurrence rate of HCC, as well as whether DAAs can be used for hepatitis C in HCC patients after antitumor treatment and the efficacy of DAAs in such patients...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
68490
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"